BioLife Solutions Management
Management criteria checks 2/4
BioLife Solutions' CEO is Rod de Greef, appointed in Oct 2023, has a tenure of less than a year. total yearly compensation is $6.39M, comprised of 3.1% salary and 96.9% bonuses, including company stock and options. directly owns 0.15% of the company’s shares, worth $1.13M. The average tenure of the management team and the board of directors is 2.4 years and 15.4 years respectively.
Key information
Rod de Greef
Chief executive officer
US$6.4m
Total compensation
| CEO salary percentage | 3.1% |
| CEO tenure | less than a year |
| CEO ownership | 0.1% |
| Management average tenure | 2.4yrs |
| Board average tenure | 15.4yrs |
Recent management updates
Recent updates
Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?
Mar 12
BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price
Feb 19BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion
Dec 19Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term
Aug 17Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?
Aug 11Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?
May 06Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?
Feb 22Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?
Jan 10Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?
Dec 10BioLife: What The Future Holds
Oct 19BioLife Solutions COO Roderick de Greef to retire
Oct 03BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?
Sep 27BioLife Solutions GAAP EPS of -$1.71 misses by $1.50, revenue of $40.5M beats by $1.33M
Aug 09BioLife Solutions: Sell-Side Posture Overly Optimistic, Rate Neutral
Jul 29Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?
Jun 15BioLife: Can This Company Successfully Turn Around?
Apr 18Temporary Setbacks At BioLife
Mar 02Is BioLife Solutions (NASDAQ:BLFS) A Risky Investment?
Jan 11BioLife: Poised For Growth
Dec 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$6m | US$199k | -US$66m |
| Sep 30 2023 | n/a | n/a | -US$102m |
| Jun 30 2023 | n/a | n/a | -US$83m |
| Mar 31 2023 | n/a | n/a | -US$146m |
| Dec 31 2022 | US$2m | US$450k | -US$140m |
| Sep 30 2022 | n/a | n/a | -US$106m |
| Jun 30 2022 | n/a | n/a | -US$96m |
| Mar 31 2022 | n/a | n/a | -US$15m |
| Dec 31 2021 | US$1m | US$412k | -US$9m |
| Sep 30 2021 | n/a | n/a | US$5m |
| Jun 30 2021 | n/a | n/a | US$4m |
| Mar 31 2021 | n/a | n/a | -US$20m |
| Dec 31 2020 | US$3m | US$391k | US$2m |
| Sep 30 2020 | n/a | n/a | US$7m |
| Jun 30 2020 | n/a | n/a | US$16m |
| Mar 31 2020 | n/a | n/a | US$39m |
| Dec 31 2019 | US$1m | US$403k | -US$2m |
| Sep 30 2019 | n/a | n/a | -US$32m |
| Jun 30 2019 | n/a | n/a | -US$39m |
| Mar 31 2019 | n/a | n/a | -US$44m |
| Dec 31 2018 | US$490k | US$350k | -US$25m |
| Sep 30 2018 | n/a | n/a | US$1m |
| Jun 30 2018 | n/a | n/a | -US$146k |
| Mar 31 2018 | n/a | n/a | -US$2m |
| Dec 31 2017 | US$520k | US$300k | -US$3m |
Compensation vs Market: Rod's total compensation ($USD6.39M) is above average for companies of similar size in the US market ($USD3.44M).
Compensation vs Earnings: Rod's compensation has increased whilst the company is unprofitable.
CEO
Rod de Greef (63 yo)
less than a year
Tenure
US$6,387,586
Compensation
Mr. Roderick de Greef, also known as Rod, serves as Director of BioLife Solutions, Inc. since January 03, 2023 and serves as its Chief Executive Officer & Chairman since October 20, 2023. He had been Presi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | less than a year | US$6.39m | 0.15% $ 1.1m | |
| Chief Financial Officer | 2.4yrs | US$1.70m | 0.28% $ 2.1m | |
| Chief Quality & Operations Officer | less than a year | US$1.12m | 0.35% $ 2.7m | |
| Chairman of Scientific Advisory Board | 4.3yrs | US$1.35m | 0.70% $ 5.4m | |
| Chief Marketing Officer | 9.2yrs | US$734.45k | 0.29% $ 2.2m | |
| Chief Human Resources Officer | 3.3yrs | no data | 0.14% $ 1.1m | |
| Chief Revenue Officer | less than a year | no data | 0.26% $ 2.0m |
2.4yrs
Average Tenure
51yo
Average Age
Experienced Management: BLFS's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 1.3yrs | US$6.39m | 0.15% $ 1.1m | |
| Chairman of Scientific Advisory Board | no data | US$1.35m | 0.70% $ 5.4m | |
| Member of Scientific Advisory Board | 17.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 16.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 17.5yrs | no data | no data | |
| Independent Director | 10.4yrs | US$253.75k | 0.097% $ 741.1k | |
| Member of the Scientific Advisory Board | no data | US$284.00k | no data | |
| Member of Scientific Advisory Board | 16.6yrs | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Lead Director | 3yrs | US$269.17k | 0.065% $ 496.4k | |
| Independent Director | 2.5yrs | US$250.00k | 0.091% $ 693.1k | |
| Member of Scientific Advisory Board | 15.4yrs | no data | no data |
15.4yrs
Average Tenure
57.5yo
Average Age
Experienced Board: BLFS's board of directors are seasoned and experienced ( 15.4 years average tenure).